Checkmate 744: Subgroup Analyses of an International Trial for Relapsed Pediatric Hodgkin Lymphoma

Name: Checkmate 744: Subgroup Analyses of an International Trial for Relapsed Pediatric Hodgkin Lymphoma
Uploaded: 2019-08-07T00:00:00+00:00
Description: Kara Kelly, MD, Chair of the Department of Pediatric Oncology at Roswell Park Comprehensive Cancer Center, presents a subgroup analyses of an international trial for relapsed pediatric Hodgkin Lymphoma.

Kara Kelly, MD, Chair of the Department of Pediatric Oncology at Roswell Park Comprehensive Cancer Center, presents a subgroup analyses of an international trial for relapsed pediatric Hodgkin Lymphoma.

Created by

Related Presenters

Kara Kelly, MD

Professor of Oncology
Chair, Department of Pediatric Oncology
Waldemar J. Kaminski Endowed Chair of Pediatrics

My name is Dr. Kara Kelly, and I’m a pediatric oncologist and the Chair of Roswell Park Oishei Children’s Cancer and Blood Disorders Program.

Related Videos

Video

New Targets for Acute Myeloid Leukemia

Eunice Wang, MD, Chief of Leukemia Service at Roswell Park Comprehensive Cancer Center, discusses the emergence of new therapeutic options for the treatment of Acute Myeloid Leukemia.

Video

New Imaging Guidelines for Monoclonal Plasma Cell Disorders

Jens Hillengass, MD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, reviews new imaging guidelines for multiple myeloma, as well as other monoclonal plasma cell disorders, that were published in The Lancet Oncology.

Video

CAR T-cell and Transplant: Cellular Therapies for Malignant Disease

Philip McCarthy, MD, Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, provides an overview of the utilization of T-Cell therapies for malignant diseases, with an emphasis on immune effector therapy.

Video

When Cancer Looks Like Something Else: How Does Mutational Profiling Inform the Diagnosis of Myelodysplasia?

Elizabeth Griffiths, MD, Director of MDS at Roswell Park Comprehensive Cancer Center, discusses what MDS is, describes the mutational profiling in normal aging, as well as in MDS, and instructs on how to distinguish mutations from the disease.

Video

Transplant Eligibilty for Myeloma Patients

Jens Hillengass, MD, gives a presentation on myeloma treatments and the types of patients who are transplant eligible and those who are non-transplant eligible.